News Hopstem maps course to bring stem cell stroke therapy to US China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.
News Stroke data breathes life back into Bayer's asundexian Prospects for Bayer's oral Factor XIa inhibitor asundexian have improved markedly after a phase 3 trial in secondary stroke prevention.
News Roche ends the 30-year US hiatus in new stroke drugs Genentech has won FDA approval for its clot-buster TNKase as a treatment for acute ischaemic stroke, after almost abandoning the project in 2023.
R&D Sponsored Innovative sublingual medication for improved stroke care Stroke poses a major threat to public health, and this threat is predicted to worsen in the years to come.
Digital Sponsored Embracing innovation to drive clinical change in UK stroke c... Medical technology (MedTech) companies go through a vigorous process to introduce their solutions into a clinical environment.
R&D Allogeneic cell therapy isn’t dead, with Brian Culley Lineage Cell Therapeutics' Brian Culley discusses allogeneic cell therapy, even beyond the traditional cell therapy realm of oncology.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.